Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A.

Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. No abstract available.

PMID:
24988929
[PubMed - in process]
2.

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials.

Ardizzoni A, Tiseo M, Boni L.

Eur J Cancer. 2014 Jun 26. pii: S0959-8049(14)00742-4. doi: 10.1016/j.ejca.2014.06.002. [Epub ahead of print]

PMID:
24981975
[PubMed - as supplied by publisher]
3.

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.

Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A.

Anticancer Res. 2014 Jun;34(6):3185-8.

PMID:
24922692
[PubMed - in process]
4.

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.

Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.

PMID:
24898067
[PubMed - in process]
Free PMC Article
5.

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.

Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A.

Tumori. 2014 Jan-Feb;100(1):e20-3. doi: 10.1700/1430.15832.

PMID:
24675505
[PubMed - indexed for MEDLINE]
6.

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M, Bortesi B, Goldoni M, Silini EM, De Palma G, Mutti A, Ardizzoni A.

Lung Cancer. 2014 Feb;83(2):265-71. doi: 10.1016/j.lungcan.2013.12.001. Epub 2013 Dec 12.

PMID:
24388705
[PubMed - in process]
7.

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, Fantini R, Rossi G.

Tumori. 2013 Sep-Oct;99(5):e229-32. doi: 10.1700/1377.15321.

PMID:
24362875
[PubMed - indexed for MEDLINE]
8.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1.

PMID:
24355409
[PubMed - in process]
9.

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G.

Endocr Relat Cancer. 2013 Dec 16;21(1):1-16. doi: 10.1530/ERC-13-0246. Print 2014 Feb.

PMID:
24344249
[PubMed - in process]
10.

YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.

Corradi M, Goldoni M, Alinovi R, Tiseo M, Ampollini L, Bonini S, Carbognani P, Casalini A, Mutti A.

Anticancer Res. 2013 Dec;33(12):5517-24.

PMID:
24324091
[PubMed - indexed for MEDLINE]
11.

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.

Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, Ruffini L, Bartolotti M, Bortesi B, Fumarola C, Caffarra C, Cavazzoni A, Alfieri RR, Petronini PG, Bordonaro R, Bruzzi P, Ardizzoni A, Soto Parra HJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):299-307. doi: 10.1007/s00280-013-2356-x. Epub 2013 Nov 21.

PMID:
24258456
[PubMed - indexed for MEDLINE]
12.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR.

PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013.

PMID:
24167634
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

MET and ALK as Targets for the Treatment of NSCLC.

Capelletti M, Gelsomino F, Tiseo M.

Curr Pharm Des. 2014;20(24):3914-32.

PMID:
24138716
[PubMed - in process]
14.

Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer.

Mozzoni P, Banda I, Goldoni M, Corradi M, Tiseo M, Acampa O, Balestra V, Ampollini L, Casalini A, Carbognani P, Mutti A.

Biomarkers. 2013 Dec;18(8):679-86. doi: 10.3109/1354750X.2013.845610. Epub 2013 Oct 8.

PMID:
24102090
[PubMed - indexed for MEDLINE]
15.

NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI.

Facchinetti F, Tiseo M, Gnetti L, Silini EM, Ardizzoni A.

Lung Cancer. 2013 Oct;82(1):177-8. doi: 10.1016/j.lungcan.2013.07.018. Epub 2013 Aug 13. No abstract available.

PMID:
23953757
[PubMed - indexed for MEDLINE]
16.

Is immunohistochemistry always required to diagnose lung cancer?

Rossi G, Tiseo M, Cavazza A, Colby TV.

Adv Anat Pathol. 2013 Sep;20(5):327-33. doi: 10.1097/PAP.0b013e3182a28a24. Review.

PMID:
23939149
[PubMed - indexed for MEDLINE]
17.

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.

Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.

PMID:
23860535
[PubMed - indexed for MEDLINE]
18.

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M.

J Thorac Oncol. 2013 Aug;8(8):1091-4. doi: 10.1097/JTO.0b013e318293d88c.

PMID:
23857399
[PubMed - indexed for MEDLINE]
19.

Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules.

De Filippo M, Saba L, Concari G, Nizzoli R, Ferrari L, Tiseo M, Ardizzoni A, Sverzellati N, Paladini I, Ganazzoli C, Sconfienza LM, Carrafiello G, Brunese L, Genovese EA, Ampollini L, Carbognani P, Rusca M, Zompatori M, Rossi C.

Radiol Med. 2013 Oct;118(7):1071-81. doi: 10.1007/s11547-013-0965-4. Epub 2013 Jul 25.

PMID:
23856805
[PubMed - indexed for MEDLINE]
20.

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.

Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A; Bio-FAST trial group.

Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2.

PMID:
23549037
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk